Med Biogene Inc  

(Public, CVE:MBI)   Watch this stock  
Find more results for MBI
+0.0050 (11.11%)
Delayed:   10:03AM EDT
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.05 - 0.05
52 week 0.03 - 0.10
Open 0.05
Vol / Avg. 68,000.00/31,543.00
Mkt cap 4.32M
P/E     -
Div/yield     -
EPS -0.01
Shares 86.58M
Beta 2.46
Inst. own     -

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -535.06% -174.17%
Return on average equity -1733.95% -784.28%
CDP Score - -


598 East Kent Avenue South
+1-604-7328821 (Phone)
+1-604-7324801 (Fax)

Website links


Med BioGene Inc. (MBI) is a Canadian-based life science company. The Company is engaged in the development and commercialization of genomic-based clinical laboratory diagnostic tests for cancer. It’s focus is on managing the license and rights to GeneFx Lung (formerly, LungExpress Dx), a gene expression-based test for early-stage non-small-cell lung cancer. GeneFx Lung is expected to provide better-informed and personalized treatment decisions to assist in the selection of patients for adjuvant chemotherapy. MBI has partnered with Precision Therapeutics for the global commercialization of GeneFx Lung.

Officers and directors

Iain Weir-Jones Ph.D. Chairman of the Board, Chief Executive Officer
Ibrahim Ghobrial Chief Financial Officer
Devid Diebolt Director
Terence W. Friedlander Director
Shumsheer Sidhu Director
Toby Weir-Jones Director